Influence of warfarin therapy on activated factor VII clotting activity

Blood Coagulation and Fibrinolysis

Volumn 17, Issue 3, 2006, Pages 221-224

  Lippi, Giuseppe ^a,b   Montagnana, Martina ^a   Salvagno, Gian Luca ^a   Poli, Giovanni ^a   Franchini, Massimo ^b   Guidi, Gian Cesare ^a  

^a UNIVERSITY OF VERONA   (Italy)

^b UNIVERSITY HOSPITAL OF VERONA   (Italy)

Author keywords

Activated factor VII; Factor VII; Laboratory testing; Oral anticoagulants; Prothrombin time; Warfarin

Indexed keywords

ANTICOAGULANT AGENT; BLOOD CLOTTING FACTOR 7; BLOOD CLOTTING FACTOR 7A; COUMARIN ANTICOAGULANT; WARFARIN;

ADULT; AGED; ANTICOAGULANT THERAPY; ANTICOAGULATION; ARTICLE; BLOOD CLOTTING; CLINICAL ARTICLE; CORRELATION ANALYSIS; DRUG EFFICACY; DRUG MECHANISM; FEMALE; HUMAN; INTERNATIONAL NORMALIZED RATIO; MALE; PRIORITY JOURNAL; REFERENCE VALUE; THROMBOSIS;

ADULT; AGED; ANTICOAGULANTS; ATRIAL FIBRILLATION; BLOOD COAGULATION; BLOOD COAGULATION TESTS; FACTOR VII; FACTOR VII DEFICIENCY; FACTOR VIIA; FEMALE; HUMANS; MALE; MIDDLE AGED; PROTHROMBIN TIME; REFERENCE VALUES; WARFARIN;

EID: 33645525825     PISSN: 09575235     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.mbc.0000220247.97164.ea     Document Type: Article

References (27)

1. Bick RL. Antithrombotic therapy: current practice and future trends. Hematol Oncol Clin North Am 2005; 19:xi-xvi.
2. Hirsh J, Dalen J, Anderson DR, Poller L, Bussey H, Ansell J, et al. Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range. Chest 2001; 119 (Suppl):8S-21S.
3. Blann AD, Landray MJ, Lip GY. ABC of antithrombotic therapy: an overview of antithrombotic therapy. BMJ 2002; 325:762-765.
4. Antman EM. The re-emergence of anticoagulation in coronary disease. Eur Heart J 2004; 6 (Suppl B):B2-B8.
5. Barcellona D, Vannini ML, Fenu L, Balestrieri C, Marongiu F. Warfarin or acenocoumarol: which is better in the management of oral anticoagulants? Thromb Haemost 1998; 80:899-902.
6. Morrissey JH, Macik BG, Neuenschwander PF, Comp PC. Quantitation of activated factor VII levels in plasma using a tissue factor mutant selectively deficient in promoting factor VII activation. Blood 1993; 81:734-744.
7. Sakata T, Kario K, Matsuo T, Katayama Y, Matsuyama T, Kato H, et al. Suppression of plasma-activated factor VII levels by warfarin therapy. Arterioscler Thromb Vasc Biol 1995; 15:241-246.
8. Raskob GE, Durica SS, Morrissey JH, Owen WL, Comp PC. Effect of treatment with low-dose warfarin-aspirin on activated factor VII. Blood 1995; 85:3034-3039.
9. Yamada A, Wada H, Kamikura Y, Hiyoyama K, Shimura M, Nagaya S, et al. Plasma levels of activated FVII in various diseases. Blood Coagul Fibrinolysis 1996; 7:794-798.
10. Miller GJ, Bauer KA, Barzegar S, Cooper JA, Rosenberg RD. Increased activation of the haemostatic system in men at high risk of fatal coronary heart disease. Thromb Haemost 1996; 75:767-771.
11. Yee KO, Ikari Y, Schwartz SM. Un update of the Grützbalg hypothesis: the role of thrombosis and coagulation in atherosclerotic progression. Thromb Haemost 2001; 85:207-217.
12. Versteeg HH, Peppelenbosch MP, Spek CA. The pleiotropic effects of tissue factor: a possible role for factor VIIa-induced intracellular signalling? Thromb Haemost 2001; 86:1353-1359.
13. Konigsberg W, Kirchhofer D, Riederer MA, Nemerson Y. The TF:VIIa complex: clinical significance, structure-function relationships and its role in signaling and metastasis. Thromb Haemost 2001; 86:757-771.
14. Viles-Gonzalez JF, Anand SX, Zafar MU, Fuster V, Badimon JJ. Tissue factor coagulation pathway: a new therapeutic target in atherothrombosis. J Cardiovasc Pharmacol 2004; 43:669-776.
15. Hoffman M, Monroe DM 3rd. The action of high-dose factor VIIa (FVIIa) in a cell-based model of hemostasis. Semin Hematol 2001; 38:6-9.
16. Wilcox JN, Smith KM, Schwartz SM, Gordon D. Localization of tissue factor in the normal vessel wall and in the atherosclerotic plaque. Proc Natl Acad Sci USA 1989; 86:2839-2843.
17. Colucci M, Balconi G, Lorenzet R, Pietra A, Locati D, Donati MB, et al. Cultured human endothelial cells generate tissue factor in response to endotoxin. J Clin Invest 1983; 71:1893-1896.
18. Sorensen BB, Hedner U. Erhardtsen E. rFVIIai in acute coronary syndromes. Semin Vasc Med 2003; 3:199-204.
19. Junker R, Heinrich J, Schulte H, van de Loo J, Assmann G. Coagulation factor VII and the risk of coronary heart disease in healthy men. Arterioscler Thromb Vasc Biol 1997; 17:1539-1544.
20. Colucci M, Balconi G, Lorenzet R, Pietra A, Locati D, Donati MB, et al. Relationships between homocysteine, factor VIIa, and thrombin generation in acute coronary syndromes. Circulation 2000; 101:372-377.
21. Girelli D, Russo C, Ferraresi P, Olivieri O, Pinotti M, Friso S, Manzato F, et al. Polymorphisms in the factor VII gene and the risk of myocardial infarction in patients with coronary artery disease. N Engl J Med 2000; 343:774-780.
22. Franchini M, Capra F, Capelli C, De Maria E, Lippi G, Gandini G. Clinical efficacy of recombinant activated factor VII (rFVIIa) during acute bleeding episode and surgery in a patient with acquired hemophilia A with high inhibitor titer. Haematologica 2001; 86:E12.
23. Berntorp E. Recombinant FVIIa in the treatment of warfarin bleeding. Semin Thromb Hemost 2000; 26:433-435.
24. Deveras RA, Kessler CM. Reversal of warfarin-induced excessive anticoagulation with recombinant human factor VIIa concentrate. Ann Intern Med 2002; 137:884-888.
25. Hoffman M. Laboratory monitoring of high-dose factor VIIa therapy [letter]. Ann Intern Med 2003; 139:791.
26. Cid AR, Lorenzo JI, Haya S, Montoro JM, Casana P, Aznar JA. A comparison of FVII:C and FVIIa assays for the monitoring of recombinant factor VIIa treatment. Haemophilia 2001; 7:39-41.
27. Goudemand J, Caron C, Dreyfus M, Sie P, and the Haemostasis Standardization Group of the Groupe d'Etude Hemostase et Thrombose. Standardization of factor VII/activated factor VII measurement in plasma of patients treated with recombinant factor activated VII. Blood Coagul Fibrinolysis 2003; 14:505-511.